drugset / Trial / NCT06356675
A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy
Phase 4
Not yet recruiting
33 enrolled
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
NaSingle-groupOpen-labelTreatment
Summary
Immune resistance after treatment, there is no standard treatment, one of the most important and the most effective measures is immune to combination therapy。Targeted angiogenesis therapy has always been the focus of research on the treatment of NSCLC patients with progressive disease after immunotherapy. From the mechanism of action, angiogenesis and immunosuppression are interrelated processes.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2028-07-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |